Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Should You Sell?

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $9.04, but opened at $8.59. Sysmex shares last traded at $8.91, with a volume of 1,823 shares traded.

Analyst Ratings Changes

Separately, Citigroup downgraded shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Sysmex Stock Performance

The company has a current ratio of 3.33, a quick ratio of 2.44 and a debt-to-equity ratio of 0.12. The firm’s 50-day moving average is $8.75 and its two-hundred day moving average is $9.17. The stock has a market cap of $5.60 billion, a price-to-earnings ratio of 23.42 and a beta of 1.10.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). Sysmex had a return on equity of 7.28% and a net margin of 7.13%.The company had revenue of $877.92 million for the quarter, compared to analyst estimates of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, sell-side analysts expect that Sysmex Corporation ADR will post 0.37 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.